Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: Disclosed embodiments include rendering systems configured to: (i) after receiving a request from a user to render a creative work associated with a non-fungible token, determining (a) whether the user owns the non-fungible token and (b) a current render count corresponding to how many times the creative work associated with the non-fungible token has been previously rendered; and (ii) when the user owns the non-fungible token and the current render count indicates that the creative work has been previously rendered fewer than a maximum render count corresponding to a preconfigured total number of authorized renderings of the creative work associated with the non-fungible token, (a) obtaining an implementation file corresponding to the creative work, (b) rendering the creative work according to the implementation file, and (c) updating the current render count to reflect another rendering of the creative work.

Abstract: A method for computer numerically controlled processing may include generating a user interface to enable the configuration of an edge treatment. The user interface may also be generated to enable the configuration of a design corresponding to a combination of the first object and the second object generated by applying one of a plurality of Boolean operation. A computer numerically controlled machine may be configured to deliver an electromagnetic energy in order to effect, in a material, one or more changes corresponding to the edge treatment and/or the design configured by the user. For example, the one or more changes corresponding to the edge treatment may include a variable depth engraving along at least a portion of a perimeter of a material.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present invention provides a combination of genomic and computational technologies to provide rapid, portable sample analysis for sequencing or identifying a target sequence involving generating probes for use in analyzing a sample which may comprise a target sequence.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: A computing device is described that displays a set of graphical elements in a status bar of a graphical user interface. Each graphical element corresponds to a different pending notification. While expanding a notification shade from the status bar, the device displays the graphical elements within an area of the notification shade that is adjacent to a leading edge of the notification shade. Responsive to determining that a particular notification message is newly visible, the device removes, a particular graphical element that corresponds to the particular notification message, and displays the particular graphical element within the particular notification message. In this manner, interaction with the notification area may be more efficient, as during a process of expanding or contracting this area, the user may be informed the underlying state of the set of pending notifications as a whole.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: A computing device is described that displays a set of graphical elements in a status bar of a graphical user interface. Each graphical element corresponds to a different pending notification. While expanding a notification shade from the status bar, the device displays the graphical elements within an area of the notification shade that is adjacent to a leading edge of the notification shade. Responsive to determining that a particular notification message is newly visible, the device removes, a particular graphical element that corresponds to the particular notification message, and displays the particular graphical element within the particular notification message. In this manner, interaction with the notification area may be more efficient, as during a process of expanding or contracting this area, the user may be informed the underlying state of the set of pending notifications as a whole.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: A computing device is described that displays a set of graphical elements in a status bar of a graphical user interface. Each graphical element corresponds to a different pending notification. While expanding a notification shade from the status bar, the device displays the graphical elements within an area of the notification shade that is adjacent to a leading edge of the notification shade. Responsive to determining that a particular notification message is newly visible, the device removes, a particular graphical element that corresponds to the particular notification message, and displays the particular graphical element within the particular notification message. In this manner, interaction with the notification area may be more efficient, as during a process of expanding or contracting this area, the user may be informed the underlying state of the set of pending notifications as a whole.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: Disclosed are systems and methods for detecting the specific location, orientation, surface plane(s) and scale of a real-world object, and providing an augmented reality (AR) experience of the object based therefrom. The disclosed systems and method provide a novel, efficient and accurate mechanism for launching an AR application that provides an AR view of a captured or currently being viewed image. The instant disclosure's AR positioning and tracking systems and methods provide a streamlined system that maximizes the device's computational resources in order to accurately determine and track the viewed object's and the capturing device's positioning and orientation, as well as the object's physical dimensions, thereby ensuring an efficiently produced AR experience.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.